ストックスクリーナーアプリを入手
24.08
2.03%
-0.4989
アフターアワーズ：
24.13
0.0486
+0.20%
前日終値:
$24.58
開ける：
$24.11
24時間の取引高:
866
Relative Volume:
0.95
時価総額：
$2.27B
収益：
-
当期純損益:
$-104.24M
株価収益率:
-10.29
EPS:
-2.34
ネットキャッシュフロー:
$-87.22M
1週間 パフォーマンス:
-4.92%
1か月 パフォーマンス:
-49.36%
6か月 パフォーマンス:
-49.36%
1年 パフォーマンス:
-49.36%
1日の値動き範囲:
$24.07
$24.13
1週間の範囲:
$24.07
$25.34
52週間の値動き範囲:
$23.72
$26.16
Dice Therapeutics Inc Stock (DICE) Company Profile
名前
Dice Therapeutics Inc
セクター
電話
650-566-1402
住所
279 East Grand Avenue, Suite 300 Lobby B, South San Francisco
Compare DICE vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DICE
Dice Therapeutics Inc
|
24.08 | 2.27B | 0 | -104.24M | -87.22M | -2.34 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dice Therapeutics Inc Stock (DICE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-03-31 | 開始されました | Needham | Buy |
| 2023-03-01 | 開始されました | Cowen | Outperform |
| 2023-03-01 | 開始されました | TD Cowen | Outperform |
| 2022-11-15 | 開始されました | Guggenheim | Buy |
| 2022-09-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-09-07 | 開始されました | Stifel | Buy |
| 2022-07-18 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-11 | 開始されました | BofA Securities | Buy |
| 2021-10-11 | 開始されました | Evercore ISI | Outperform |
| 2021-10-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Dice Therapeutics Inc (DICE) 最新ニュース
Talawar Therapeutics Appoints Industry Veterans Mittie Doyle, MD, and Susannah Gray to Board of Directors - PR Newswire
InventHelp Inventor Develops New Card and Dice Combination Game (CHK-6005) - Yahoo Finance
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - The Globe and Mail
Tema Launches Trading & Prediction Markets ETF (DICE) - Yahoo Finance
DICE Therapeutics Inc. (DICE) Peer Comparison – Compare with Others - Value Research
DICE Therapeutics Inc. (DICE) Key Financial Ratios – Valuation, Profitability & More - Value Research
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors - The Manila Times
Autoimmune Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
DHI Group (DHX) Stock Sees Fair Value Lift As Analysts Weigh ClearanceJobs And Dice - Yahoo Finance
Segment Overview and Major Growth Areas in the Urokinase Market - openPR.com
DHI Group Inc (DHX) (Q2 2026) Earnings Call Highlights: ClearanceJobs Surges 24% While DICE ... - Yahoo Finance
CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors - PR Newswire
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology - Eli Lilly and Company
MindWare Brings a New Reiner Knizia Game and a Giant Dice Tower to Gen Con 2026 - Yahoo Finance
A 'Made in the USA' Monopoly edition cost twice as much to build — and no US factory could even make the dice - Yahoo Finance
An InventHelp 123Invent Client Develops New Money Themed Dice Game (LBT-9813) - Yahoo Finance
The EU rolls dice by setting unambiguous parameters for Satcos operating in 2GHz - Yahoo Finance
Tech Professionals Find Relevant Roles Faster with Dice’s LLM Connector - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Morningstar Sees SpaceX Worth Half Its IPO Price - thedeepdive.ca
OpenAI Files Confidential S-1 With SEC, Targeting IPO as Soon as Q4 - thedeepdive.ca
SpaceX Cuts IPO Valuation Target to $1.8 Trillion After Investor Feedback - TheDeepDive.ca
TWO DICE SECURES STRATEGIC INVESTMENT FROM OAK VIEW GROUP - Yahoo Finance
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire
Russia is about to roll the dice on crypto regulation. Here’s its playbook - Yahoo Finance
Jim Cramer on JetBlue Airways: “It’s a Dice Roll, and I Don’t Like Dice Rolls” - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More - 24/7 Wall St.
EA Slashes Battlefield Headcount In a Pivot to AI - Yahoo Finance
Burnout, layoffs, 'ghost jobs' in Dice's 2026 tech survey - Stock Titan
Muted and missing M&As: JPM deals absent in 2026 - BioWorld News
Baron of Dice Answers the Questions Players Keep Asking - Yahoo Finance
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Boyd Gaming reveals $160M revamp for Par-A-Dice Casino - Yahoo Finance
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes - American Heart Association Journals
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
Don't Buy Summit Therapeutics Until This Big Thing Happen - The Motley Fool
Here Are Wednesday's Top Wall Street Analyst Research Calls: DHL Group, NetApp, Nutanix, Oracle, Snowflake, Urban Outfitters, Zscaler and More - 247wallst.com
Big pharma drives surge in biopharma job cuts in 2025 - BioWorld News
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy - Business Wire
Updated: DICE rolls on as lead oral IL-17 candidate meets proof-of-concept in PhI trial, sending shares higher - Endpoints News
EA May Sell BioWare And DICE Or Close Other Studios, Says Analyst - Yahoo Finance
RNA Therapeutics Market Size to Reach USD 26.13 Billion by 2034 - BioSpace
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - PR Newswire
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant - Fierce Pharma
Fever Acquires Ticketing Platform Dice - Yahoo Finance
Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology - Endpoints News
DHI Group Inc (DHX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Focus - Yahoo Finance
Dice Therapeutics Stock Price, News & Analysis - Stock Titan
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld News
Dice Therapeutics Inc (DICE) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):